Nijmegen - NovioGendix, the molecular biomarker company developing tests for GU cancer diagnosis, prognosis and .... Read more..
NovioGendix, based in Nijmegen (The Netherlands), is a molecular diagnostic research and service company providing an expert-based, integrated approach in developing advanced and clinically useful molecular diagnostic assays for the uro-oncological practice.
NovioGendix Research focuses on biomarker-based diagnostic product development for uro-oncological diseases. In its R&D program the company conducts multiple retrospective and prospective clinical studies in prostate-, bladder- and kidney cancer.
NovioGendix Servicelab has transferred the ProgensaŽ PCA3 testing services to DDL-NMDL in Rijswijk, the Netherlands.